Article - 25/07/2011 Cell culture technology: hamster cells and the production of biopharmaceuticals Biopharmaceuticals are one of the best selling drugs. The majority of successful biopharmaceutical ingredients are produced in CHO cell lines. Strong competition forces biopharmaceutical producers to continuously improve the drug development process and the production methods, which requires highly qualified experts.https://www.gesundheitsindustrie-bw.de/en/article/news/cell-culture-technology-hamster-cells-and-the-production-of-biopharmaceuticals
Article - 25/07/2011 Christian Thoma – the control of translation enables the rapid regulation of cellular processes Heisenberg fellow PD Dr. Christian Thoma from the Freiburg University Medical Centre has been focusing on the regulation of translation for a number of years and has established a method that enables him to investigate translation on the molecular level. Thoma and his team have come a step closer to their goal of finding targets for the therapy of cancer and hepatitis C.https://www.gesundheitsindustrie-bw.de/en/article/news/christian-thoma-the-control-of-translation-enables-the-rapid-regulation-of-cellular-processes
Article - 25/07/2011 Cell culturing as a taught subject: many more “Biberachs” are needed Cell culture technology is only taught at a handful of universities. However, this interdisciplinary subject is the core of the “Pharmaceutical Biotechnology” programme offered by the Biberach University of Applied Sciences. We talked about the subject with Professor Jürgen Hannemann, founding dean of the “Pharmaceutical Biotechnology” programme, and with Professor Friedemann Hesse, who runs the “cell culture technology” teaching programme.https://www.gesundheitsindustrie-bw.de/en/article/news/cell-culturing-as-a-taught-subject-many-more-biberachs-are-needed
Article - 25/07/2011 Silke Brüderlein has “green fingers” for cell cultures Many researchers in the biosciences work with cell cultures, but not all of them seem to understand them at a deeper level. The biologist Silke Brüderlein from the Institute of Pathology in Ulm is a specialist in cell culture and is well aware of the problems that might arise when working with cell cultures.https://www.gesundheitsindustrie-bw.de/en/article/news/silke-bruederlein-has-green-fingers-for-cell-cultures
Dossier - 25/07/2011 Cell culture technology: it all started with frog nerve fibres The history of cell culture technology is closely connected with cell biology and the discoveries made in the field of cell biology. Ever since the study of science became a professional activity, researchers have been trying to keep cells and tissues alive outside organisms for purposes of investigation. https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-culture-technology-it-all-started-with-frog-nerve-fibres
Article - 25/07/2011 The mixture is key: what cells like to feed on Dr. Aziz Cayli knows CHO (Chinese hamster ovary) cells so well that he decided to establish his own company in 2005. Prior to establishing CellCa GmbH in the city of Laupheim, Cayli held posts at Roche in Penzberg and Boehringer Ingelheim in Biberach. CellCa is a specialist in upstream processing and with its current total of 15 staff, the company achieved revenues of around two million euros in 2009. We talked with Dr. Aziz Cayli who did his…https://www.gesundheitsindustrie-bw.de/en/article/news/the-mixture-is-key-what-cells-like-to-feed-on
Press release - 23/07/2011 Innovative strength in Baden-Württemberg The Baden-Württemberg Ministry of Finance and Economics presented the results of two studies that evaluated the innovative strength of Baden-Württemberg in comparison to other regions around the world. The studies were carried out by the University of Hohenheim and the independent research institute BAK Basel Economics AG BAK Basel on behalf of the Baden-Württemberg Ministry of Finance and Economics and they were financed by the Baden-Württemberg…https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-strength-in-baden-wuerttemberg
Press release - 21/07/2011 Phenex wins the former Head of Diabetes and Metabolic Diseases at Sanofi Aventis as advisor Phenex Pharmaceuticals AG today announced the engagement of Prof. Dr. Dr. Werner Kramer, the former Head of Diabetes and Metabolic Diseases R&D at Sanofi Aventis, as a senior scientific advisor. At the end of last year, Prof. Kramer has left Sanofi Aventis after 25 years of very successful practice in drug discovery and development to devote himself to new scientific challenges. His long- and outstanding expertise in research and development…https://www.gesundheitsindustrie-bw.de/en/article/press-release/phenex-wins-the-former-head-of-diabetes-and-metabolic-diseases-at-sanofi-aventis-as-advisor
Press release - 20/07/2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer Roche announced on July 19th that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm is a global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche’s Tissue Diagnostics (Ventana Medical Systems, Inc.) business…https://www.gesundheitsindustrie-bw.de/en/article/press-release/roche-acquires-mtm-laboratories-ag-expanding-offering-in-cervical-cancer
Article - 18/07/2011 Titanium screws and stem cells for dental implants How are we supposed to chew and smile when the tooth fairy comes to fetch our second set of teeth? When it’s difficult to tell the difference between modern tooth implants and real teeth in both technical and aesthetical terms, people who lose their teeth due to accidents or age very quickly regain their smile. However, there needs to be enough bone to hold and support the implant. Prof. Dr. Dr. Ralf Gutwald and his team in the Department of Oral…https://www.gesundheitsindustrie-bw.de/en/article/news/titanium-screws-and-stem-cells-for-dental-implants
Article - 18/07/2011 JRS – creating sustainability with fibres Fibres can be used to disintegrate tablets, bind together the ingredients in a formulation and coat substrates. The company J. RETTENMAIER & SÖHNE GmbH+Co.KG has been offering plant fibres, pulp and cellulose for a broad range of applications since 1878. The company now also uses the natural fibres for the fabrication of bioplastics in an effort to contribute to sustainability.https://www.gesundheitsindustrie-bw.de/en/article/news/jrs-creating-sustainability-with-fibres
Press release - 15/07/2011 HITS Participates in a new DFG Research Unit on Blood Coagulation Scientists from the Heidelberg Institute for Theoretical Studies participate in a new Research Unit on blood coagulation sponsored by the German Research Foundation (DFG). The aim of the DFG funding is to support a successful existing cooperation between scientists over several years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hits-participates-in-a-new-dfg-research-unit-on-blood-coagulation
Press release - 13/07/2011 Kinetochores prefer the “silent” DNA sections of the chromosome The centromere is a specialized region of the chromosome, on which a protein complex known as the kinetochore is assembled. During cell division, the kinetochore provides a point of attachment for molecules of the cytoskeleton, thereby mediating the segregation of chromosomes to the two opposing cell poles. Scientists from the Max Planck Institute of Immunobiology and Epigenetics and BIOSS in Freiburg have investigated the factors that play an…https://www.gesundheitsindustrie-bw.de/en/article/press-release/kinetochores-prefer-the-silent-dna-sections-of-the-chromosome
Article - 12/07/2011 Deeper insight into the activity of the cortex Visual and tactile objects in our surroundings are translated into a perception by complex interactions of neurons in the cortex. The principles underlying spatial and temporal organization of neuronal activity during decision-making and object perception are not well understood yet. Jason Kerr from Max Planck Institute for Biological Cybernetics in Tübingen, in collaboration with Winfried Denk from the Max Planck Institute for Medical Research…https://www.gesundheitsindustrie-bw.de/en/article/news/deeper-insight-into-the-activity-of-the-cortex
Press release - 12/07/2011 Cortisol Controls Recycling of Bile Acids Scientists of the German Cancer Research Center DKFZ have made a discovery in mice whose liver cells are unable to receive cortisol signals This hormone is responsible for a process in which the liver recycles bile acids from the blood. If this recycling is disrupted the animals develop gallstones and lose weight because they are no longer able to digest dietary fats.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cortisol-controls-recycling-of-bile-acids
Dossier - 04/07/2011 Implants of the future: bioactive, corrosion-resistant and antibacterial People’s life expectancy is increasing due to constantly improving medical treatment. One result of this is the greater wear of joints, which then need to be replaced with implants. Increased life expectancy means that the implants remain in the body for much longer and therefore need to be longer lasting. The revision rate of implant materials used in clinical practice is still as much as 10 per cent, particularly in the case of hip and knee…https://www.gesundheitsindustrie-bw.de/en/article/dossier/implants-of-the-future-bioactive-corrosion-resistant-and-antibacterial
Article - 04/07/2011 Synthetic tendons made from bicomponent fibres Organs are not the only things to be transplanted. Sometimes tendons also need to be replaced. At St. Gallen-based Empa (Swiss Federal Laboratories for Materials Science and Technology), an interdisciplinary team of scientists is working on the development of synthetic tendons for surgical applications. The synthetic tendons are made of bicomponent fibres that decompose efficiently in the body after implantation.https://www.gesundheitsindustrie-bw.de/en/article/news/synthetic-tendons-made-from-bicomponent-fibres
Article - 04/07/2011 Stefan Rensing investigates the evolutionary transition from algae to land plants The biologist Prof. Dr. Stefan Rensing from the University of Freiburg has been involved in introducing the use of computers to the life sciences from the very beginning. His analyses of the moss genomes now help to close an important gap in evolutionary research how did algae become land plants?https://www.gesundheitsindustrie-bw.de/en/article/news/stefan-rensing-investigates-the-evolutionary-transition-from-algae-to-land-plants
Article - 04/07/2011 Orthobion GmbH: biomaterials for spinal implants If one takes a closer look at the mechanisms involved in bone growth, it turns out that the supposedly simple issue as to how bones grow cannot be fully answered. Konstanz-based Orthobion GmbH investigates and produces targeted biomaterials for use in implants designed for the treatment of spinal column defects. The surface structures of materials and how they affect the adhesion of bones to implant surfaces are key issues in the production of…https://www.gesundheitsindustrie-bw.de/en/article/news/orthobion-gmbh-biomaterials-for-spinal-implants
Article - 04/07/2011 Gingiva grown in Petri dishes We use teeth to break down food and gum disease is the major cause of tooth loss. Our teeth are firmly anchored in the jaw bone and surrounded and supported by the gum (gingiva), one of the five types of tissue that make up the human periodontium. A complex interplay of biomolecules maintains homoeostasis, i.e. the natural balance, in the gum tissue. A team of researchers led by Prof. Dr. Pascal Tomakidi from the Freiburg University Medical…https://www.gesundheitsindustrie-bw.de/en/article/news/gingiva-grown-in-petri-dishes
Article - 04/07/2011 The use of regenerative biomaterials is likely to grow Tuttlingen-based Aesculap AG is committed to using different materials including ceramics, titanium and high-performance polymers for the development and production of implants. The medical technology company has come up with a solution to prevent people from developing allergies against substances used in prostheses. Dr. Harald Stallforth, CEO Research & Development and Vice Chairman of the Aesculap AG management board talks with a BioLAGO…https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-regenerative-biomaterials-is-likely-to-grow
Article - 04/07/2011 The adhesion of cells to the endothelium and to artificial surfaces Professor Stefan W. Schneider from the Mannheim Medical Faculty is investigating the function of the vascular endothelium and its interaction with blood and tumour cells using microfluidics methods that enable him to measure the adhesion of cells to the walls of blood vessels under physiological flow conditions. As part of an interdisciplinary project, he is investigating the characteristics of wafer-thin surfaces covered with living cells, which…https://www.gesundheitsindustrie-bw.de/en/article/news/the-adhesion-of-cells-to-the-endothelium-and-to-artificial-surfaces
Press release - 30/06/2011 Cancer treatments: New information from fission yeast When a cell divides the genetic information in the chromosomes must be passed on error-free to the daughter cells. Researchers at the Friedrich Miescher Laboratory in Tübingen are studying this process using fission yeast as a model organism. In cooperation with researchers at the University of Tübingen they succeeded in attributing additional tasks to the Aurora enzymes which were already recognized as important cellular tools for the reliable…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-treatments-new-information-from-fission-yeast
Press release - 28/06/2011 Constitution of Health Axis Europe signed Health technology clusters in Cambridge (UK), Leuven (Belgium) and Heidelberg (Germany) agreed on the formation of the Health Axis Europe alliance to foster health innovation across Europe.https://www.gesundheitsindustrie-bw.de/en/article/press-release/constitution-of-health-axis-europe-signed
Press release - 28/06/2011 Ulcerative colitis: Lipid Therapeutics announces start of Phase IIb clinical trial Lipid Therapeutics, a biotechnology company, announced today that it has initiated a Phase IIb clinical trial with its lead product LT-02 in patients with ulcerative colitis. Lipid Therapeutics received approval for this multi-center, international trial from the authorities in Germany and Lithuania and is awaiting approval in Romania. Patient enrollment has already started in Germany and Lithuania.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulcerative-colitis-lipid-therapeutics-announces-start-of-phase-iib-clinical-trial